These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

991 related items for PubMed ID: 26681527

  • 21. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
    Hendrix N, Ollendorf DA, Chapman RH, Loos A, Liu S, Kumar V, Linder JA, Pearson SD, Veenstra DL.
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1210-1217. PubMed ID: 30479197
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P, Halliday A, Aassi M, Subramanian S, Jain M, Griffiths CEM.
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis.
    Rouse NC, Farhangian ME, Wehausen B, Feldman SR.
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(6):877-84. PubMed ID: 26488186
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
    Croxtall JD.
    Am J Clin Dermatol; 2012 Apr 01; 13(2):135-7. PubMed ID: 22201419
    [Abstract] [Full Text] [Related]

  • 31. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH.
    Br J Dermatol; 2009 Jun 01; 160(6):1264-72. PubMed ID: 19120346
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status.
    Feldman SR, Zhang J, Martinez DJ, Lopez-Gonzalez L, Marchlewicz EH, Shrady G, Mendelsohn AM, Zhao Y.
    J Dermatolog Treat; 2021 Mar 01; 32(2):203-211. PubMed ID: 31769703
    [Abstract] [Full Text] [Related]

  • 34. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.
    Ovejero-Benito MC, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Abad-Santos F, Daudén E.
    Am J Clin Dermatol; 2018 Apr 01; 19(2):209-222. PubMed ID: 28921458
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.
    Pan F, Brazier NC, Shear NH, Jivraj F, Schenkel B, Brown R.
    Value Health; 2011 Apr 01; 14(5):652-6. PubMed ID: 21839402
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Infliximab for the treatment of adults with psoriasis.
    Loveman E, Turner D, Hartwell D, Cooper K, Clegg A.
    Health Technol Assess; 2009 Jun 01; 13 Suppl 1():55-60. PubMed ID: 19567215
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 50.